LUXEMBOURG VILLE, Luxembourg, Jan. 26, 2015 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) S.A., today announced the signing of an exclusive worldwide license for commercial use of the PyroVir software and related knowledge database and know-how with the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, and the Centre Hospitalier Universitaire de Toulouse.
The PyroVir software developed by the laboratory of Professor Jacques Izopet is an effective tool to interpret HIV Tropism next generation sequencing (NGS) information and guide the adaptation of anti-HIV treatment.
The purpose of the software is to identify the tropism of an individual patient’s HIV strains and shows whether the patient is infected with virus that enters cells using the R5 co-receptor (patient healthy longer), the X4 co-receptor, or both (tropism switch over the course of the disease).
“PyroVir is completing our interpretive product portfolio for HIV as we are now offering analysis and interpretation systems for most of the HIV drugs targets and associated resistance for all HIV subtypes” said Dr Chalom B. Sayada, CEO of ABL. “PyroVir has been developed with high quality standards, together with extended scientific validation and specifically tailored for NGS data. These aspects were important for us to link it with our current DeepChek® HIV system”.
“PyroVir offers added values and more sensitive interpretations than standard conventional Sanger based methods, and a less expensive and more portable test than phenotypic assays”, said Pr. Jacques Izopet, head of Biology pole at Toulouse University Hospital. “We have a well validated interpretation for the main NGS platforms together with the main HIV virus subtypes, and are looking to have PyroVir more widely accessible through our partnership with Inserm, CHU de Toulouse and ABL.”
Financial details of this licensing agreements were not disclosed.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL’s products also received CE-marking for IVD use.
ABL’s products, ViroScore® Suite and DeepChek®, are for research use only in the United States, and the upcoming data processing module (DPM) is an FDA registered class I medical device. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping, and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data.
For more information, go to www.ablsa.com
Media Contact: Chalom B. SAYADA, Advanced Biological Laboratories, +35226388921, info@ablsa.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Help employers find you! Check out all the jobs and post your resume.
